Synthaverse S.A. (SVE.WA)
PLN 4.7
(2.85%)
PLN 4.7
(2.85%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 4.75 Million PLN | -21.76% |
| 2022 | 6.08 Million PLN | 43.12% |
| 2021 | 4.24 Million PLN | -4.28% |
| 2020 | 4.43 Million PLN | 78.78% |
| 2019 | 2.48 Million PLN | 107.66% |
| 2018 | -32.41 Million PLN | -5612.24% |
| 2017 | 588 Thousand PLN | 102.5% |
| 2016 | -23.47 Million PLN | 36.96% |
| 2015 | -37.24 Million PLN | -22918.18% |
| 2014 | 163.21 Thousand PLN | -93.01% |
| 2013 | 2.33 Million PLN | 143.99% |
| 2012 | -5.31 Million PLN | -1112.47% |
| 2011 | 524.59 Thousand PLN | -79.35% |
| 2010 | 2.54 Million PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -394 Thousand PLN | -110.19% |
| 2024 Q2 | 1.41 Million PLN | 459.39% |
| 2023 Q4 | 3.86 Million PLN | 260.03% |
| 2023 Q3 | -2.41 Million PLN | -194.23% |
| 2023 Q2 | 2.56 Million PLN | 245.69% |
| 2023 FY | 4.75 Million PLN | -21.76% |
| 2023 Q1 | 742 Thousand PLN | -71.14% |
| 2022 Q4 | 2.57 Million PLN | 67.38% |
| 2022 Q3 | 1.53 Million PLN | -43.78% |
| 2022 Q2 | 2.73 Million PLN | 460.42% |
| 2022 Q1 | -758 Thousand PLN | -124.81% |
| 2022 FY | 6.08 Million PLN | 43.12% |
| 2021 Q1 | -1.18 Million PLN | -132.65% |
| 2021 Q2 | 2.95 Million PLN | 349.66% |
| 2021 Q3 | -577 Thousand PLN | -119.52% |
| 2021 FY | 4.24 Million PLN | -4.28% |
| 2021 Q4 | 3.05 Million PLN | 629.46% |
| 2020 Q4 | 3.62 Million PLN | 3757.45% |
| 2020 FY | 4.43 Million PLN | 78.78% |
| 2020 Q1 | 1.14 Million PLN | -24.92% |
| 2020 Q2 | -426 Thousand PLN | -137.21% |
| 2020 Q3 | 94 Thousand PLN | 122.07% |
| 2019 FY | 2.48 Million PLN | 107.66% |
| 2019 Q1 | 207 Thousand PLN | 100.68% |
| 2019 Q2 | 402 Thousand PLN | 94.2% |
| 2019 Q3 | 349 Thousand PLN | -13.18% |
| 2019 Q4 | 1.52 Million PLN | 336.96% |
| 2018 Q4 | -30.33 Million PLN | -3789.23% |
| 2018 Q3 | -780 Thousand PLN | 3.7% |
| 2018 Q2 | -810 Thousand PLN | -67.01% |
| 2018 Q1 | -485 Thousand PLN | -103.95% |
| 2018 FY | -32.41 Million PLN | -5612.24% |
| 2017 Q3 | 53 Thousand PLN | 100.49% |
| 2017 FY | 588 Thousand PLN | 102.5% |
| 2017 Q4 | 12.26 Million PLN | 23045.28% |
| 2017 Q2 | -10.74 Million PLN | -1419.38% |
| 2017 Q1 | -707 Thousand PLN | 93.28% |
| 2016 Q3 | -3.19 Million PLN | 67.43% |
| 2016 Q4 | -10.52 Million PLN | -230.0% |
| 2016 FY | -23.47 Million PLN | 36.96% |
| 2016 Q1 | 36 Thousand PLN | 100.11% |
| 2016 Q2 | -9.79 Million PLN | -27308.33% |
| 2015 Q2 | -353 Thousand PLN | 84.35% |
| 2015 Q3 | -1.84 Million PLN | -423.51% |
| 2015 FY | -37.24 Million PLN | -22918.18% |
| 2015 Q4 | -32.78 Million PLN | -1674.15% |
| 2015 Q1 | -2.25 Million PLN | -204.53% |
| 2014 Q3 | -1.99 Million PLN | -19938.38% |
| 2014 FY | 163.21 Thousand PLN | -93.01% |
| 2014 Q1 | 14.42 Thousand PLN | -97.18% |
| 2014 Q2 | -9973.00 PLN | -169.12% |
| 2014 Q4 | 2.15 Million PLN | 207.94% |
| 2013 Q4 | 511.6 Thousand PLN | -54.67% |
| 2013 Q2 | 159.96 Thousand PLN | -70.18% |
| 2013 Q3 | 1.12 Million PLN | 605.54% |
| 2013 Q1 | 536.4 Thousand PLN | 112.93% |
| 2013 FY | 2.33 Million PLN | 143.99% |
| 2012 Q4 | -4.14 Million PLN | -241.48% |
| 2012 FY | -5.31 Million PLN | -1112.47% |
| 2012 Q2 | -276.61 Thousand PLN | -184.62% |
| 2012 Q3 | -1.21 Million PLN | -339.05% |
| 2012 Q1 | 326.9 Thousand PLN | 0.0% |
| 2011 FY | 524.59 Thousand PLN | -79.35% |
| 2010 FY | 2.54 Million PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioceltix S.A. | -13.68 Million PLN | 134.762% |
| BIOTON S.A. | 2.27 Million PLN | -109.143% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | 106.741% |
| Mabion S.A. | 41.26 Million PLN | 88.471% |
| Molecure S.A. | -18.3 Million PLN | 125.988% |
| NanoGroup S.A. | -7.88 Million PLN | 160.306% |
| Pharmena S.A. | 28.94 Million PLN | 83.56% |
| Poltreg S.A. | -13.55 Million PLN | 135.112% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | 113.33% |
| Ryvu Therapeutics S.A. | -92.11 Million PLN | 105.165% |
| Urteste S.A. | -5.58 Million PLN | 185.177% |